According to Zhitong Finance APP, BRAINAURORA-B (06681) opened more than 3% higher, rising 3.35% as of press time to HK$1.235, with a turnover of HK$5.0783 million.
On the news front, BRAINAURORA-B announced that the Company received in the evening of October 27, 2026 a Class II medical device registration certificate issued by the Beijing Municipal Medical Products Administration (Beijing Administration) for its cognitive function assessment software for patients with depression.
The product is a standalone software for cognitive function assessment in patients with depression, evaluating and producing results across four major dimensions: memory, attention, executive function, and information processing speed, so as to help clinicians understand patients' cognitive status and provide safe and effective evidence for subsequent treatment. The clinical trial of the product was launched in September 2024 and completed in August 2025.
The announcement stated that the product is the first medical device registration certificate obtained by the Company from the Beijing Administration, and also the first medical device registration certificate for cognitive function assessment in the field of depression, marking a registration breakthrough for the Company in the field of cognitive assessment of mental illness, securing a first-mover position in the market, and further improving the Company's layout of digital medical products for cognitive disorders.
The Board believes that the above registration achievement will help consolidate the Group's industry position in the field of digital medicine for cognitive disorders and is in the overall interests of the Group and its shareholders.
Comments